Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Core Insights - Vertex Pharmaceuticals announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the RUBY-3 trial at the ASN Kidney Week 2025 [1] Group 1: Drug Information - Pove is an investigational recombinant fusion protein therapeutic [1] - Pove acts as a dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines [1]